Skip to main content
Top
Published in: European Radiology 2/2004

01-02-2004 | Experimental

Distribution of Intramyocardially injected extracellular MR contrast medium: effects of concentration and volume

Authors: Gabriele A. Krombach, Ronald Baireuther, Charles B. Higgins, Maythem Saeed

Published in: European Radiology | Issue 2/2004

Login to get access

Abstract

The purpose of this study was to assess the potential of intramyocardially injected Gd-DTPA solution as a marker for distribution of intramyocardially delivered therapeutic solutions. The effects of concentration and volume of the extracellular MR contrast medium Gd-DTPA on signal intensity and spatial extent of enhancement was determined after intramyocardial delivery. In anesthetized pigs (n=11), mixtures of Gd-DTPA (0.15, 0.1 and 0.05 mmol/ml) and Evan’s blue tissue dye (3%) were injected into the wall of the left ventricle. In each pig 1 ml of 0.15 mmol/ml, 2 ml of 0.1 ml and 3 ml of 0.05 mmol/ml Gd-DTPA were injected remote from each other. Arterial blood pressure, heart rate and ECG were monitored throughout the procedure. Five minutes after injections were performed, the pigs were killed and the hearts excised. T1-weighted spin-echo MR images were acquired to measure regional signal intensity (SI) and extent of the enhanced regions. The hearts were sliced and mass of blue stained regions was determined and compared with mass of enhanced areas on MRI. Gd-DTPA significantly (p<0.001) increased regional SI compared with remote myocardium in a concentration dependent fashion (109±4% at 0.05 mmol/ml, 202±7% at 0.1, and 327±6% at 0.15) while the mass of enhanced region was 0.6±0.1 g after injection of 1 ml, 1.4±0.2 g after 2 ml and 2.3±0.3 g after 3 ml (p<0.001). Regression and Bland-Altman analysis revealed that there was close correlation and agreement between MRI and histomorphometry (r=0.98, p<0.001). Magnitude and spatial extent of enhancement depend on concentration and volume of injected contrast medium. Intramyocardial injection of extracellular MR contrast media may be useful as a marker for the extent of distribution of intramyocardially delivered therapeutic solutions.
Literature
1.
go back to reference Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, Epstein SE, Unger EF (1994) Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89:2183PubMed Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, Epstein SE, Unger EF (1994) Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89:2183PubMed
2.
go back to reference Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM (1998) Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98:2800PubMed Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM (1998) Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98:2800PubMed
3.
go back to reference Symes JF, Losordo DW, Vale PR, Lathi KG, Esakoff DD, Mayskiy M, Ismer JM (1999) Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 68:830CrossRefPubMed Symes JF, Losordo DW, Vale PR, Lathi KG, Esakoff DD, Mayskiy M, Ismer JM (1999) Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 68:830CrossRefPubMed
4.
go back to reference Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch RR, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG (1999) Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100:468PubMed Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch RR, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG (1999) Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100:468PubMed
5.
go back to reference Mack CA, Patel SR, Schwarz EA, Zanzonico P, Hahn RT, Ilercil A, Devereux RB, Goldsmith SJ, Christian TF, Sanborn TA, Kovesdi I, Hackett N, Isom OW, Crystal RG, Rosengart TK (1998) Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 115:168PubMed Mack CA, Patel SR, Schwarz EA, Zanzonico P, Hahn RT, Ilercil A, Devereux RB, Goldsmith SJ, Christian TF, Sanborn TA, Kovesdi I, Hackett N, Isom OW, Crystal RG, Rosengart TK (1998) Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 115:168PubMed
6.
go back to reference Sarkar N, Rück A, Källner G, Y-Hassan S, Blomberg P, Islam KB, Van der Linden J, Lindblom D, Nygren AT, Lind B, Brodin LA, Drvota V, Sylven C (2001) Effects of intramyocardial injection of phVEGEF-A165 as sole therapy in patients with refractory coronary artery disease—12-month follow-up: angiogenic gene therapy. J Intern Med 250:373 Sarkar N, Rück A, Källner G, Y-Hassan S, Blomberg P, Islam KB, Van der Linden J, Lindblom D, Nygren AT, Lind B, Brodin LA, Drvota V, Sylven C (2001) Effects of intramyocardial injection of phVEGEF-A165 as sole therapy in patients with refractory coronary artery disease—12-month follow-up: angiogenic gene therapy. J Intern Med 250:373
7.
go back to reference Lazarous DF, Scheinowitz M, Shou M, Hodge E, Rajanayagam S, Hunsberger S, Robinson WG Jr, Stiber JA, Correa R, Epstein SE, Unger EF (1995) Effect of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 91:145PubMed Lazarous DF, Scheinowitz M, Shou M, Hodge E, Rajanayagam S, Hunsberger S, Robinson WG Jr, Stiber JA, Correa R, Epstein SE, Unger EF (1995) Effect of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 91:145PubMed
8.
go back to reference Giordano FJ, Ping P, McKirnan D, Nozaki S, DeMaria AN, Dillmann WH, Mathieu-Costello O, Hammond HK (1996) Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nature Med 2:534PubMed Giordano FJ, Ping P, McKirnan D, Nozaki S, DeMaria AN, Dillmann WH, Mathieu-Costello O, Hammond HK (1996) Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nature Med 2:534PubMed
9.
go back to reference Henry T, Annex B, Azrin M (1999) Final results of the VIVA trial of rhVEGF for human therapeutic angiogenesis. Circulation 100 (Suppl I):I476 Henry T, Annex B, Azrin M (1999) Final results of the VIVA trial of rhVEGF for human therapeutic angiogenesis. Circulation 100 (Suppl I):I476
10.
go back to reference Simons M (2000) Phase II, multicenter, double-blind, placebo-controlled, dose-finding study for safety, pharmacokinetics, and efficacy of recombinant fibroblast growth factor (rFGF-2) in subjects with coronary artery disease (CAD): FGF-2 Initiating Revascularization Support Trial (FIRST). J Am Coll Cardiol 36:310CrossRefPubMed Simons M (2000) Phase II, multicenter, double-blind, placebo-controlled, dose-finding study for safety, pharmacokinetics, and efficacy of recombinant fibroblast growth factor (rFGF-2) in subjects with coronary artery disease (CAD): FGF-2 Initiating Revascularization Support Trial (FIRST). J Am Coll Cardiol 36:310CrossRefPubMed
11.
go back to reference Laham RJ, Rezaee M, Post M, Sellke FW, Braeckman RA, Hung D, Simons M (1999) Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab Dispos 27:821PubMed Laham RJ, Rezaee M, Post M, Sellke FW, Braeckman RA, Hung D, Simons M (1999) Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab Dispos 27:821PubMed
12.
go back to reference Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, Nakao K (1998) Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lessions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98:2108PubMed Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, Nakao K (1998) Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lessions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98:2108PubMed
13.
go back to reference Schumacher B, Pecher P, Specht BU von, Stegmann TH (1998) Induction of neoangiogenesis in ischemic myocardium by human growth factors. Circulation 97:645PubMed Schumacher B, Pecher P, Specht BU von, Stegmann TH (1998) Induction of neoangiogenesis in ischemic myocardium by human growth factors. Circulation 97:645PubMed
14.
go back to reference Lederman RJ, Guttman MA, Peters DC, Thompson RB, Sorger JM, Dick AJ, Raman VK, McVeigh ER (2002) Catheter-based endomyocardial injection with real-time magnetic resonance imaging. Circulation 105:1282PubMed Lederman RJ, Guttman MA, Peters DC, Thompson RB, Sorger JM, Dick AJ, Raman VK, McVeigh ER (2002) Catheter-based endomyocardial injection with real-time magnetic resonance imaging. Circulation 105:1282PubMed
15.
go back to reference Saeed M, Lee M, Martin A, Krombach GA, Weber O, Lee M, Schalla S, Higgins CB (2002) Feasibility of direct transcatheter delivery of therapeutics to the myocardium using dual X-ray-MR imaging. Int Soc Magn Reson Med, 10th Sci Meeting 18–24 May 2002, p 340 Saeed M, Lee M, Martin A, Krombach GA, Weber O, Lee M, Schalla S, Higgins CB (2002) Feasibility of direct transcatheter delivery of therapeutics to the myocardium using dual X-ray-MR imaging. Int Soc Magn Reson Med, 10th Sci Meeting 18–24 May 2002, p 340
16.
go back to reference Yang X, Atalar E, Li D, Serfaty JM, Wang D, Kumar A, Cheng L (2001) Magnetic resonance imaging permits in vivo monitoring of catheter-based vascular gene delivery. Circulation 104:1588PubMed Yang X, Atalar E, Li D, Serfaty JM, Wang D, Kumar A, Cheng L (2001) Magnetic resonance imaging permits in vivo monitoring of catheter-based vascular gene delivery. Circulation 104:1588PubMed
17.
go back to reference Krombach GA, Higgins CB, Günther RW, Kuehne T, Saeed M (2002) MR contrast media for cardiovascular imaging. RoFo 174:819CrossRef Krombach GA, Higgins CB, Günther RW, Kuehne T, Saeed M (2002) MR contrast media for cardiovascular imaging. RoFo 174:819CrossRef
18.
go back to reference Kuehne T, Saeed M, Reddy G, Akbari H, Gleason K, Turner D, Teitel D, Moore P, Higgins CB (2001) Sequential MR monitoring of pulmonary with endovascular stents placed across the pulmonary valve in growing swine. Circulation 104:2363PubMed Kuehne T, Saeed M, Reddy G, Akbari H, Gleason K, Turner D, Teitel D, Moore P, Higgins CB (2001) Sequential MR monitoring of pulmonary with endovascular stents placed across the pulmonary valve in growing swine. Circulation 104:2363PubMed
19.
go back to reference Saeed M, Lund G, Wendland MF, Bremerich J, Weinmann HJ, Higgins CB (2001) Magnetic resonance characterization of the peri-infarction zone of reperfused myocardial infarction using necrosis specific and extracellular nonspecific contrast media. Circulation 103:871PubMed Saeed M, Lund G, Wendland MF, Bremerich J, Weinmann HJ, Higgins CB (2001) Magnetic resonance characterization of the peri-infarction zone of reperfused myocardial infarction using necrosis specific and extracellular nonspecific contrast media. Circulation 103:871PubMed
20.
go back to reference Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307PubMed Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307PubMed
21.
go back to reference Lathi KG, Vale PR, Losordo DW, Cespedes RM, Symes JF, Esakof DD, Maysky M, Isner JM (2001) Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results. Anesth Analg 92:19PubMed Lathi KG, Vale PR, Losordo DW, Cespedes RM, Symes JF, Esakof DD, Maysky M, Isner JM (2001) Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results. Anesth Analg 92:19PubMed
22.
go back to reference Saeed M, Higgins CB, Geschwind JF, Wendland MF (2000) T1-relaxation kinetics of extracellular, intracellular and intravascular MR contrast agents in normal and acutely reperfused infarcted myocardium using echoplanar MR imaging. Eur Radiol 10:310PubMed Saeed M, Higgins CB, Geschwind JF, Wendland MF (2000) T1-relaxation kinetics of extracellular, intracellular and intravascular MR contrast agents in normal and acutely reperfused infarcted myocardium using echoplanar MR imaging. Eur Radiol 10:310PubMed
23.
go back to reference Geschwind JF, Saeed M, Wendland MF, Higgins CB (1998) Depiction of reperfused myocardial infarction using contrast enhanced spin echo with gradient echo MR imaging: influence of dose of MR contrast media. Invest Radiol 33:386CrossRefPubMed Geschwind JF, Saeed M, Wendland MF, Higgins CB (1998) Depiction of reperfused myocardial infarction using contrast enhanced spin echo with gradient echo MR imaging: influence of dose of MR contrast media. Invest Radiol 33:386CrossRefPubMed
24.
go back to reference Lipton MJ, Bogaert J, Boxt LM, Reba RC (2002) Imaging of ischemic heart disease. Eur Radiol 12:1061CrossRefPubMed Lipton MJ, Bogaert J, Boxt LM, Reba RC (2002) Imaging of ischemic heart disease. Eur Radiol 12:1061CrossRefPubMed
25.
go back to reference Sandstede JJ (2003) Assessment of myocardial viability by MR imaging. Eur Radiol 13:52PubMed Sandstede JJ (2003) Assessment of myocardial viability by MR imaging. Eur Radiol 13:52PubMed
26.
go back to reference Lazarous DF, Shou M, Stiber JA, Dadhania DM, Thirumurti V, Hodge E, Unger EF(1997) Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res 36:78 Lazarous DF, Shou M, Stiber JA, Dadhania DM, Thirumurti V, Hodge E, Unger EF(1997) Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res 36:78
27.
go back to reference Grossman PM, Han Z, Palasis M, Barry JJ, Lederman RJ (2002) Incomplete retention after direct myocardial injection. Cathet Cardiovasc Intervent 55:392CrossRef Grossman PM, Han Z, Palasis M, Barry JJ, Lederman RJ (2002) Incomplete retention after direct myocardial injection. Cathet Cardiovasc Intervent 55:392CrossRef
28.
go back to reference Rezaee M, Yeung AC, Altman P, Lubbe D, Takeshi S, Schwartz RS, Stertzer S, Altman JD (2001) Evaluation of the percutaneous intramyocardial injection for local myocardial treatment. Cathet Cardiovasc Intervent 53:271–276CrossRef Rezaee M, Yeung AC, Altman P, Lubbe D, Takeshi S, Schwartz RS, Stertzer S, Altman JD (2001) Evaluation of the percutaneous intramyocardial injection for local myocardial treatment. Cathet Cardiovasc Intervent 53:271–276CrossRef
Metadata
Title
Distribution of Intramyocardially injected extracellular MR contrast medium: effects of concentration and volume
Authors
Gabriele A. Krombach
Ronald Baireuther
Charles B. Higgins
Maythem Saeed
Publication date
01-02-2004
Publisher
Springer-Verlag
Published in
European Radiology / Issue 2/2004
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-003-2148-5

Other articles of this Issue 2/2004

European Radiology 2/2004 Go to the issue